Paid Clinical Trials for Myeloma

Showing all 7 results

Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL

by CTG

in Lymphoma, Leukemia, Myeloma

Other

Texas

Deadline:

07/01/2035

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

by CTG

in Multiple Myeloma, Myeloma

Other

Illinois

Deadline:

06/01/2026

HEME Home Transfusion Program

by CTG

in Hematologic Malignancy, Leukemia, Myelodysplastic Syndromes, Hematologic Diseases, Myeloma

Other

Massachusetts

Deadline:

05/31/2029

FT576 in Subjects With Multiple Myeloma

by CTG

in Myeloma, Multiple Myeloma

Other

Alabama

Deadline:

02/01/2040

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

by CTG

in Multiple Myeloma, Refractory Multiple Myeloma, Myeloma

Other

Massachusetts

Deadline:

12/31/2034

Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT

by CTG

in Lymphoma, Myeloma, Stem Cell Transplant Complications, Allogeneic and Autologous Stem Cell Transplant

Other

Ohio

Deadline:

12/31/2026

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

by CTG

in Myeloma

Other

Pennsylvania

Deadline:

07/11/2026

Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

HEME Home Transfusion Program

FT576 in Subjects With Multiple Myeloma

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps

Get new clinical trials sent to you?

Paid Clinical Trials for Myeloma

Filter Results:

Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

HEME Home Transfusion Program

FT576 in Subjects With Multiple Myeloma

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps